An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Safety and Efficacy of INCB054828 in Combination with Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer with Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Pemigatinib (Primary)
Indications Adenocarcinoma; Gastric cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 May 2024 Status changed from recruiting to completed.
06 Sep 2022 Status changed from not yet recruiting to recruiting.
24 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight

Ask the expert

Thank you

At a glance

Most Recent Events

You need to be a logged in or subscribed to view this content Request demo

Table of Contents

New Timelines Chart